RxDoctor Payments Data

Ilana Rachshtut, MD

Family Medicine · Kutztown, PANPI 1396774279

Payments from drug & device makers

$267in general payments, 2019–2025

Across 15 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$87
  • AstraZeneca$59
  • Amgen$47
  • Lilly USA, LLC$25
  • GSK$20
  • Novo Nordisk$16
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$18670%
  • Education$8030%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$267 in reported general payments places this provider in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$199,229
Medicare patients
451
Services billed
2,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$127,052
EliquisApixaban98$97,704
JardianceEmpagliflozin101$91,050
Tresiba Flextouch U-200Insulin Degludec40$49,345
MounjaroTirzepatide26$46,755
XareltoRivaroxaban41$42,820
XifaxanRifaximin24$37,001
Tresiba Flextouch U-100Insulin Degludec35$34,400
TradjentaLinagliptin36$32,225
TrulicityDulaglutide16$29,726
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$25,837
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$20,635
Breo ElliptaFluticasone/Vilanterol20$12,698
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$12,603
RybelsusSemaglutide11$11,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30$16$141,971120 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$87$130,980154 claims
Lilly USA, LLCMounjaro, Trulicity$25$76,48142 claims
GSKTrelegy Ellipta, Breo Ellipta$20$38,53543 claims
AstraZenecaSymbicort$59$2,72812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Kutztown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →